Share Name Share Symbol Market Type Share ISIN Share Description
Provexis Plc LSE:PXS London Ordinary Share GB00B0923P27 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.025p -5.26% 0.45p 0.40p 0.50p 0.45p 0.45p 0.45p 2,423,515 14:42:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Food Producers 0.2 -0.4 -0.0 - 8.19

Provexis Share Discussion Threads

Showing 46026 to 46045 of 46050 messages
Chat Pages: 1842  1841  1840  1839  1838  1837  1836  1835  1834  1833  1832  1831  Older
DateSubjectAuthorDiscuss
19/9/2017
17:19
Probably not.
librag
19/9/2017
16:05
Are you going to buy the book?
lafin
19/9/2017
16:00
It's good to learn. Try it.
librag
19/9/2017
15:52
Of course I won't understand a word of it so I won't bother reading it.
lafin
19/9/2017
15:47
New book by Asim Duttaroy called "Nutraceuticals and Human blood platelet function: Application in Cardiovascular Health ". Says on his website It will be published by Wiley, UK, in July, 2017.
lafin
19/9/2017
15:40
Your quote is apt ... look in the mirror, a shortened version is better. "You can't see that you cannot think". If you don't understand the nuances of our IP, perhaps it might be better if you posted less and read more.
librag
19/9/2017
14:44
You can't see that you cannot think outside of your medical training.
lafin
18/9/2017
23:01
He won't like that! Thanks BB. I was attempting(and failing) to make it look scientific which was a bit ridiculous as I am not a scientist.
lafin
18/9/2017
21:58
Lafin Re "There is no terminology for people who may be at risk of future ailments .." Actually, there is, and you've already stated it, it's called "at risk" , which basically means some people are, from a statistical point of view, significantly more likely to suffer serious medical problems than other people of their age / background etc. Plainly, when it comes to CVD, taking a Fruitflow pill isn't their only option, they could, for example :- Quit Smoking and / or Exercise More and / or Drink Less and / or Eat a healthy Mediterranean diet But most won't, and, if people like Graham, who understand the risks of the above, continue to be lethargic porkies who want a quick fix, then the trick, from a business perspective, is to sell them the quick fix and take their money. The fact that it'll probably do them some good is an added bonus BB
bareknee
18/9/2017
17:21
That was a guess.
lafin
18/9/2017
17:15
There is no terminology for people who may be at risk of future ailments so they have to use medical terminology.
lafin
18/9/2017
17:07
You are nit picking just so you can type something.
lafin
18/9/2017
14:39
Why would you want a silly discussion like that on a share board about a product which is intended to be a dietary supplement? It is NOT intended for ILL people. It's for people who do not want to become ill.
lafin
18/9/2017
13:20
From 2008. hxxps://www.researchgate.net/publication/23567799_The_Effects_of_Natural_Antioxidants_from_Tomato_Extract_in_Treated_but_Uncontrolled_Hypertensive_Patients Just tomato extract (equivalent to 4 medium size tomatoes), not FF. Works though, so we're back to diet vs supplements ... discuss.
librag
18/9/2017
12:45
Good news, FF reduces blood pressure in pre-hypertensive subjects. Not the same as saying it will work with truly hypertensive patients but it's a good start. Be nice to know by how much. ACEIs are big business.
librag
18/9/2017
12:17
Some Blood pressure research found by gixer HttP://www.tandfonline.com/doi/abs/10.1080/09637486.2017.1376621?journalCode=iijf20& Abstract In order to investigate whether the angiotensin converting enzyme-inhibitory tomato extract Fruitflow® would lower blood pressure after consumption, we conducted a randomised, double-blinded, placebo-controlled human intervention study, involving 12 pre-hypertensive people in a crossover design. Consuming a single dose of 150 mg Fruitflow® resulted in a significant reduction in 24-hour average blood pressure as well as average wake-period and sleep-period SBP, compared to placebo. Other parameters related to blood pressure, such as 24-hour average mean arterial pressure, pulse pressure, heart rate, central aortic systolic pressure and radial augmentation index were also reduced. In addition, the platelet aggregation response to ADP, measured 24 hours after consuming Fruitflow®, fell significantly compared to baseline, and compared to placebo. This pilot study clearly shows the beneficial effects of Fruitflow® on two important cardiovascular risk factors, high blood pressure and platelet hyperactivity.
lafin
14/9/2017
13:25
AND "The company and its commercial partner DSM saw an encouraging increase in brand awareness and customer interest in Fruitflow in recent months. The total projected annual sales value of the prospective sales pipeline for Fruitflow now stands at a new all-time high level." This will be since March.
lafin
13/9/2017
10:59
Oh for goodness sake. Read Senor Sensible's post above.He is trying to help you I think. His post makes sense.
lafin
10/9/2017
02:46
Revenue of GBP227,618 this time and if more then doubles again then we will have revenue of over £500,000 next year and hopefully the admin, selling, and distribution costs will be a lot less. And of course we will also benefit once By-Health, in partnership with DSM and Provexis launches the new Fruitflow healthy heart products to the estimated 300 million Chinese potential customers. Report states New product development and launches? And Revenue more then doubled.! Well, Fruitflow plus Omega 3 is the only new product I know of so it sounds like new products are ready to be launched.IMHO However, more than doubling revenues sounds good, and if this increase in revenue continues and if the high administrative, selling and distribution costs due to new product development and launches is now under control, next results should shine. IMHO Report:- "The company, focused on the development of its Fruitflow food supplement, reported a pretax loss of GBP425,531 for the year ended in March, narrowed slightly from a loss of GBP452,711 the prior year, on revenue of GBP227,618, more than doubled from from GBP91,649." "The rise in revenue was partly offset by more administrative, selling and distribution costs, as Provexis invested in new product development and launches." Sounds like new products ready to be launched and the costly development costs etc has been covered as the above pretax loss highlights.IMHO So, all looking good as long as the costly development of the new products gets launched this year in China and around the world.IMHO
wheelds
07/9/2017
09:13
lol, AIM is a market providing seed money to small companies with the hope it will bear fruit in the future. Most pricing on AIM is speculative. if you want companies with massive turnover there are other markets such as FTSE350 to look for. PXS has been ramped, pumped and dumped in the past, which has helped finance the development of the product which is now bringing in revenue, albeit less than 1Mil last year, but the key is the revenue growth. if that continues to the point where this is self funding which could be in the next year then dilution ends. Any further revenue growth or moving into new markets, etc will underpin good shareprice rises. IMO buying in at this price is fairly de-risked but be prepared to hold and ride out any pump and dump related dips. If looking to turn a fast profit you need to be one step ahead.
senor_sensible
Chat Pages: 1842  1841  1840  1839  1838  1837  1836  1835  1834  1833  1832  1831  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170921 17:42:04